Delving into the Latest Updates on Shanghai EA therapeutics with Synapse

Overview

Tags

Other Diseases

Eye Diseases

Nervous System Diseases

Monoclonal antibody

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Hemic and Lymphatic Diseases	2
Immune System Diseases	2
Infectious Diseases	2
Endocrinology and Metabolic Disease	2
Neoplasms	1

Top 5 Drug Type	Count

Biological products	5
Monoclonal antibody	1

Top 5 Target	Count

Complement system proteins	3
TSHR(Thyroid stimulating hormone receptor)	1
C5(Complement C5)	1

一、评价EA5在中国健康成年受试者中单次剂量递增静脉注射的安全性和耐受性。二、评价EA5在中国健康成年受试者中单次剂量递增静脉注射的药代动力学（PK）特征。三、评价EA5在中国健康成年受试者中单次剂量递增静脉注射的药效动力学（PD）特征。？评价EA5在中国健康成年受试者中单次剂量递增静脉注射的免疫原性。

[Translation]

1. Evaluate the safety and tolerability of EA5 after single ascending dose intravenous injection in healthy Chinese adult subjects. 2. Evaluate the pharmacokinetic (PK) characteristics of EA5 after single ascending dose intravenous injection in healthy Chinese adult subjects. 3. Evaluate the pharmacodynamic (PD) characteristics of EA5 after single ascending dose intravenous injection in healthy Chinese adult subjects. ? Evaluate the immunogenicity of EA5 after single ascending dose intravenous injection in healthy Chinese adult subjects.

Start Date-

Sponsor / Collaborator

Shanghai EA therapeutics

[+1]

CTR20244925

/ Not yet recruitingPhase 1

一项评估EA5人源化单抗在成人阵发性睡眠性血红蛋白尿症（PNH）患者中多次给药的安全性、药代和药效学特征的多中心、开放标签的Ib期临床试验

[Translation] A multicenter, open-label, Phase Ib clinical trial evaluating the safety, pharmacokinetics, and pharmacodynamics of multiple-dose EA5 humanized monoclonal antibody in adult patients with paroxysmal nocturnal hemoglobinuria (PNH)

主要研究目的评价EA5在阵发性睡眠性血红蛋白尿症受试者中多次给药的安全性和耐受性。次要研究目的评价EA5在阵发性睡眠性血红蛋白尿症受试者中多次给药的PK、PD特征；评价EA5在阵发性睡眠性血红蛋白尿症受试者中多次给药的免疫原性。评价EA5在阵发性睡眠性血红蛋白尿症受试者中多次给药的初步有效性。

[Translation]

Main study objectives To evaluate the safety and tolerability of EA5 after multiple administration in subjects with paroxysmal nocturnal hemoglobinuria. Secondary study objectives To evaluate the PK and PD characteristics of EA5 after multiple administration in subjects with paroxysmal nocturnal hemoglobinuria; To evaluate the immunogenicity of EA5 after multiple administration in subjects with paroxysmal nocturnal hemoglobinuria. To evaluate the preliminary efficacy of EA5 after multiple administration in subjects with paroxysmal nocturnal hemoglobinuria.

Start Date-

Sponsor / Collaborator

Shanghai EA therapeutics

[+1]

100 Clinical Results associated with Shanghai EA therapeutics

Login to view more data

0 Patents (Medical) associated with Shanghai EA therapeutics

Login to view more data

100 Deals associated with Shanghai EA therapeutics

Login to view more data

100 Translational Medicine associated with Shanghai EA therapeutics

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

4

Preclinical

Phase 1

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

EA5 ( Complement system proteins )	Hemoglobinuria, Paroxysmal More	Phase 1
EA501 ( Complement system proteins )	Hemoglobinuria, Paroxysmal More	Preclinical
EA502 ( Complement system proteins )	Diabetic macular oedema More	Preclinical
EA7	Virus Diseases More	Preclinical
CN116712390 ( C5 )Patent Mining	Nervous System Diseases More	Discovery